About

Dr. Farrukh M Koraishy is a board-certified nephrologist and Professor of Medicine at Stony Brook University Hospital, where he has cared for patients since 2019. He completed his medical degree at Dow Medical College, followed by Internal Medicine residency training at Wayne State University/Detroit Medical Center. He then completed a Clinical Nephrology Fellowship at Yale University School of Medicine and earned a PhD in Investigative Medicine from the Yale Graduate School of Arts and Sciences. Dr. Koraishy provides comprehensive, evidence-based care for a wide range of kidney conditions, including Acute Kidney Injury, Chronic Kidney Disease, End-Stage Renal Disease, hypertension, kidney stones, cystic kidney diseases, glomerulonephritis, and electrolyte and fluid abnormalities. He offers timely evaluation for both urgent and routine kidney issues, emphasizing clear communication, patient education, shared decision-making, and individualized treatment plans. As a dedicated educator, he directs the Renal Module for first-year medical students at Stony Brook University School of Medicine and mentors medical students, residents, fellows, and postdoctoral trainees. His research focuses on kidney disease and its association with mental health and aging, and he has published extensively in top nephrology journals. Recognized nationally for his work, Dr. Koraishy is known for his compassionate, thorough, and highly responsive approach to patient care.

Research topics

• Medicine
• Internal medicine
• Emergency medicine
• Intensive care medicine
• Gastroenterology
• Virology
• Demography
• Pathology
• Cardiology
• Environmental health

Selected publications

• Post-nephrectomy outcomes in COVID-19 and non-COVID-19 Patients using ACEi, ARB and SGLT2i: a N3C database study

  International Urology and Nephrology · 2026-03-08 · 1 citations

  article
  PublisherDOI

• Mapping spatial and social inequities of long COVID across the United States: a retrospective cohort study

  The Lancet Regional Health - Americas · 2026-02-13

  articleOpen access

  Background: Long COVID affects a substantial portion of the U.S. population. The emergence of the Omicron variant and persistent sociodemographic disparities may contribute to temporal and regional variation in long COVID risk. However, such spatiotemporal variation and related social determinants remain poorly characterized. This study aimed to examine spatiotemporal patterns of county-level long COVID incidence and to identify sociodemographic factors associated with these patterns before and after the emergence of the Omicron variant. Methods: This retrospective study utilized data from the National COVID Cohort Collaborative (N3C), covering 5,652,474 COVID-19 cases from 2020 to 2024 and 41,694 long COVID cases across 1063 U.S. counties from 2021 to 2024. Temporal patterns of long COVID were analyzed before and after the Omicron variant's emergence, and spatial patterns were assessed using Moran's I and Getis statistics. Bayesian spatial random effect models were employed to evaluate the associations between long COVID incidence and sociodemographic factors such as economic vulnerability, healthcare access, and mobility. Findings: Among 4,070,879 COVID-19 cases analyzed, quarterly long COVID incidence ranged from 0.015% to 14.29%. Before the emergence of the Omicron variant, incidence was 204 cases per 10,000 COVID-19 cases, compared with 248 cases per 10,000 COVID-19 cases after Omicron emergence (p < 0.001). Based on the Local Moran's I statistic, 48.8% (328 of 673) of counties showed significant spatial correlation (p < 0.05) after Omicron's emergence, up from 43.5% (293 of 673) prior. High-risk areas became more concentrated in inland regions, while low-risk areas clustered along the East Coast. Long COVID incidence was significantly associated with economic vulnerability, limited healthcare access, and mobility constraints, with these sociodemographic disparities consistently driving its spatial disparities over time. Subregional analyses revealed distinct regional differences in social drivers. Interpretation: These findings highlight pronounced spatiotemporal and regional disparities in long COVID incidence across the United States. Targeted public health interventions, particularly in economically and geographically vulnerable regions, are essential to ensure equitable access to diagnosis, care, and resource allocation. Funding: National Center for Advancing Translational Sciences; National Institutes of Health; National Science Foundation.

  PublisherDOI

• Higher Incidence of CKD and ESKD Among Adults with Post-Traumatic Stress Disorder (PTSD) and Major Depressive Disorder (MDD)

  Journal of the American Society of Nephrology · 2025-10-01

  article
  PublisherDOI

• Cognitive Impairment

  Kidney360 · 2025-06-25 · 2 citations

  articleOpen accessSenior authorCorresponding

  Key Points Early cognitive impairment and dementia raise the risk of developing CKD. Early cognitive impairment and dementia are linked to faster kidney function decline. Background Emerging evidence suggests that better cognition is associated with a lower risk of CKD. However, whether early-onset cognitive impairment (CI) at baseline is linked to rapid eGFR decline or incident CKD remains unclear. Methods We conducted a prospective cohort study of 5761 World Trade Center responders (mean age, 53.8±7.9 years) without CKD at baseline, followed for a mean of 4.2±1.9 years. CI was defined as a Montreal Cognitive Assessment (MoCA) score ≤23, with a subgroup analysis for baseline dementia (MoCA ≤18). Primary outcomes included annual eGFR change and rapid eGFR decline (&lt;−5 ml/min per 1.73 m 2 per year). The secondary outcome was incident CKD (eGFR &lt;60 ml/min per 1.73 m 2 or diagnosis code). Multivariable Cox proportional hazards models and linear regressions were used for binary and continuous outcomes, respectively. Sensitivity analyses included looking at the effect of baseline mild CI (MoCA score 19–23), propensity matching for demographics, baseline age younger than 60 years, removal of baseline post-traumatic stress disorder/depression or baseline head trauma/stroke/cardiovascular disease, and after exclusion of those who died during follow-up. Results At baseline, 1446 (25%) individuals had CI, while 89 (2%) had dementia. The mean baseline eGFR was 91.1 ml/min per 1.73 m 2 , with an overall decline of −1.2 ml/min per 1.73 m 2 per year. Rapid eGFR decline occurred in 550 (10%) individuals. After adjusting for age, sex, race and ethnicity, comorbidities, World Trade Center exposure, screened post-traumatic stress disorder, and baseline eGFR, CI and dementia were significantly associated with rapid eGFR decline (adjusted hazard ratio [aHR], 1.63 and 2.42, respectively; both P &lt; 0.001) and faster annual eGFR decline. Findings were consistent across all sensitivity analyses. In addition, 248 (4%) individuals developed incident CKD. Both baseline CI (aHR, 1.72; P &lt; 0.001) and dementia (aHR, 2.77; P = 0.010) were significantly associated with incident CKD. Conclusions Among middle-aged individuals without CKD, early-onset CI was independently associated with rapid eGFR decline and incident CKD. These findings warrant validation in other cohorts.

  PublisherDOI

• A Complex Case of AKI and Hematuria

  Journal of the American Society of Nephrology · 2025-10-01

  article

  Introduction: Anti-glomerular basement membrane (GBM) disease is a rare form of glomerulonephritis (GN) that can progress rapidly to end-stage kidney disease (ESKD). While the exact trigger is often unknown, coronavirus disease 2019 (COVID-19) has been implicated in some cases. Case Description: A 55-year-old female with a history of hypertension and nephrolithiasis status post extracorporeal shock wave lithotripsy (ESWL) six months prior presented with acute kidney injury (AKI), hematuria, upper respiratory symptoms, and a positive COVID-19 PCR. She had received two COVID-19 vaccine doses in 2021 and had no prior diagnosis of COVID-19. Her baseline serum creatinine (SCr) was 0.9 mg/dL; at presentation, it was 2.51 mg/dL. Urinalysis was positive for blood and protein, with no signs of pulmonary hemorrhage. She was started on remdesivir. Initial imaging showed a non-obstructing right renal stone without hydronephrosis, but SCr continued to rise, peaking at 5.18 mg/dL. Repeat imaging revealed frank hydronephrosis, prompting bilateral ureteral stent placement. Despite intervention, renal function worsened, and hematuria persisted. Serology was negative except for markedly elevated anti-GBM antibody titers. Empiric pulse steroids and plasmapheresis were started. Renal biopsy showed diffuse necrotizing and crescentic GN with linear IgG deposits, confirming anti-GBM disease. At biopsy, creatinine was 9.2 mg/dL. Cyclophosphamide was added, but the patient progressed to uremia and anuria, requiring hemodialysis. She was discharged stable on outpatient dialysis. Discussion: This case underscores the diagnostic complexity of simultaneous AKI and hematuria from both obstructive uropathy and anti-GBM disease. While nephrolithiasis is common and easily identified via imaging, anti-GBM disease is rare and may be overlooked. ESWL and recent COVID-19 may serve as potential triggers. Clinicians should maintain a low threshold for evaluating anti-GBM disease in similar presentations.

  PublisherDOI

• Worsening Long-Term Post-Traumatic Stress Disorder (PTSD) Symptom Trajectory and Risk of Kidney Function Decline

  Journal of the American Society of Nephrology · 2025-10-01

  article1st authorCorresponding

  Background: Post-traumatic stress disorder (PTSD) is a common condition noted in World Trade Center (WTC) responders. We previously reported that PTSD was associated with accelerated decline in estimated glomerular filtration rate (eGFR). However, the long-term effects of PTSD symptom trajectories on kidney function remain unclear. Methods: This study was a prospective cohort analysis of WTC responders, followed for a median of 5.6 years since 2015 with annual protocolized eGFR assessments. PTSD symptoms were measured using the PCL-17 questionnaire. Symptom trajectories over 20 years since 9/11 were modeled using mixed effects, latent class growth, and growth mixture models to identify distinct patterns. The associations between WTC-related PTSD symptom trajectory and kidney outcomes (rapid eGFR decline - defined as a loss of >5 mL/min/1.73 m2 per year, annual eGFR change, and incident CKD) were analyzed using multivariable Poisson and Cox regression models. Secondary analyses included participants of European ancestry with polygenic risk scores (PRS) for PTSD and kidney decline. Models included PTSD symptom levels, and linear and quadratic rates of change, demographics, comorbidities, exposure severity, baseline eGFR, genetic principal components, and relevant PRSs. The outcomes were also assessed after stratification by race: ‘White’ versus ‘Non-white’ Results: Among 9308 WTC responders (mean age: 54.1 ± 8.3 years), 6% of responders had rapid eGFR decline. In the fully adjusted multivariable model, a one standard deviation increase in the linear slope of PTSD symptoms was significantly associated with increased risk of developing rapid eGFR decline in both the overall cohort (RR: 1.11 (95% CI: 1.00 – 1.22), p = 0.042) and PRS sub-group. A similar association was noted with greater eGFR decline per year. Among 9043 individuals without baseline CKD, 670 (7%) developed incident CKD. In a fully adjusted multivariable model, worsening of linear slope of PTSD was associated with risk of incident CKD (HR: 1.13 (95% CI: 1.02 – 1.24), p = 0.016). When stratified by race, non-Whites had a relatively higher risk of kidney outcomes compared to Whites. Conclusion: Among 9/11 responders, worsening symptom trajectory of PTSD is associated with significantly increased risk of rapid kidney function decline and incident CKD, possibly influenced by race.

  PublisherDOI

• Double CRRT in Profound Alcoholic Ketoacidosis and Shock: Salvage Extracorporeal Therapy in a Malnourished, Hyperosmolar Patient in the Intensive Care Unit (ICU)

  Journal of the American Society of Nephrology · 2025-10-01

  article

  Introduction: Ethanol toxicity rarely requires renal replacement therapy. However, in the presence of shock, starvation ketoacidosis, hyperosmolarity, and multi-organ dysfunction, extracorporeal support may be life-saving. Double CRRT—the simultaneous use of two CRRT circuits—is a rare rescue strategy, primarily reported in refractory lactic acidosis and toxin-induced crises. Case Description: A 47-year-old woman with alcohol and polysubstance use presented obtunded after drinking 2–3 pints of vodka daily for 7 days with no food intake. She was hypotensive (BP 50/40s), tachycardic, hypothermic, and oliguric. Labs showed pH 6.80, PCO2 10, AG 53, lactate 12, BHB 8, Cr 2.0, Na 152, serum osmolality 441, and blood alcohol level 368 mg/dL. She tested positive for fentanyl. Despite vasopressors, bicarbonate, insulin-dextrose, thiamine, and empiric antibiotics, severe acidemia persisted. Nephrology initiated dual CRRT circuits at 3:00 AM to rapidly correct acid-base and solute derangements. The second circuit was weaned by noon as her pH began to normalize. Over 72 hours, she stabilized, was transitioned to single CRRT, and remained off mechanical ventilation. She was ultimately discharged to rehab. Discussion: Double CRRT increases solute clearance and buffer delivery, enabling rapid correction of life-threatening acidosis when standard CRRT fails. This approach, described in metformin toxicity [1], has also been applied in severe intoxications and tumor lysis syndrome [2]. Limitations include catheter access, anticoagulation, and resource demands. In our case, early dual CRRT was pivotal in reversing shock and preventing intubation. Learning Points: 1-Consider dual CRRT in patients with severe acidosis unresponsive to single-circuit therapy. 2-Rapid correction of pH may prevent respiratory decompensation and mechanical ventilation. 3-Further studies are needed to guide protocolized use of double CRRT in critical care. References: 1. Reynolds HV, Pollock HHG, Apte YV, Tabah A. Achieving High Dialysis Dose via Continuous Renal Replacement Therapy in the Setting of Metformin-Associated Lactic Acidosis: A Case Series. A&A Pract. 2022;16(1):e01561. 2. De Simone E, et al. Efficacy of Continuous Venovenous Hemodiafiltration in Patients with Metformin-Associated Lactic Acidosis and Acute Kidney Injury. Sci Rep. 2025;15:8636.

  PublisherDOI

• Classification and Regression Trees analysis identifies patients at high risk for kidney function decline following hospitalization

  PLoS ONE · 2025-01-31

  articleOpen accessSenior authorCorresponding

  Estimated glomerular filtration rate (eGFR) decline is associated with negative health outcomes, but the use of decision tree algorithms to predict eGFR decline is underreported. Among patients hospitalized during the first year of the COVID-19 pandemic, it remains unclear which individuals are at the greatest risk of eGFR decline after discharge. We conducted a retrospective cohort study on patients hospitalized at Stony Brook University Hospital in 2020 who were followed for 36 months post discharge. Random Forest (RF) identified the top ten features associated with fast eGFR decline. Logistic regression (LR) and Classification and Regression Trees (CART) were then employed to uncover the relative importance of these top features and identify the highest risk patients. In the cohort of 1,747 hospital survivors, 61.6% experienced fast eGFR decline, which was associated with younger age, higher baseline eGFR, and acute kidney injury (AKI). Multivariate LR analysis showed that older age was associated with lower odds of fast eGFR decline whereas length of hospitalization and vasopressor use with greater odds. CART analysis identified length of hospitalization as the most important factor and that patients with AKI and hospitalization of 27 days or more were at highest risk. After grouping by ICU and COVID-19 status and propensity score matching for demographics, these risk factors of fast eGFR decline remained consistent. CART analysis can help identify patient subgroups with the highest risk of post-discharge eGFR decline. Clinicians should consider the length of hospitalization in post-discharge monitoring of kidney function.

  PublisherDOI

• Natural language processing for kidney ultrasound analysis: correlating imaging reports with chronic kidney disease diagnosis

  Renal Failure · 2025-08-04

  articleOpen accessSenior authorCorresponding

  INTRODUCTION: Natural language processing (NLP) has been used to analyze unstructured imaging report data, yet its application in identifying chronic kidney disease (CKD) features from kidney ultrasound reports remains unexplored. METHODS: In a single-center pilot study, we analyzed 1,068 kidney ultrasound reports using NLP techniques. To identify kidney echogenicity as either "normal" or "increased," we used two methods: one that looks at individual words and another that analyzes full sentences. Kidney length was identified as "small" if its length was below the 10th percentile. Nephrologists reviewed 100 randomly selected reports to create the reference standard (ground truth) for initial model training followed by model validation on an independent set of 100 reports. RESULTS: = 0.008). Among individuals without CKD, those with bilaterally increased echogenicity had significantly lower kidney function than those with normal echogenicity. CONCLUSIONS: State-of-the-art NLP models can accurately extract CKD-related features from ultrasound reports, with the potential of providing a scalable tool for early detection and risk stratification. Future research should focus on validating these models across different healthcare systems.

  PublisherDOI

• Estimating the Amount of Glucose Absorbed in Patients on Peritoneal Dialysis (PD) and Evaluating Its Influence on Serum Lipids and Glucose

  Journal of the American Society of Nephrology · 2025-10-01

  articleSenior author

  Background: Glycemic control is a predictor of cardiovascular complications, PD patients use dialysis solutions that contain high concentrations of glucose (g) daily. Glucose absorbtion (GA) in PD patients may contribute to adverse metabolic effects. In this study, we utilized data from the peritoneal equilibration test (PET) to estimate GA. We assessed glycemic control and lipid profiles at the initiation of PD and again after a minimum of 6 months & we Analyzed the association between the degree of GA & the characteristics of peritoneal membrane transport. Methods: we reviewed 10 pateints, from PET we extracted the D/D0 values corresponding to the dwell time specified in each patient’s PD prescription. The g amount for each dialysis cycle was calculated using the initial g concentration D0. The estimated GA in each cycle was calculated by multiplying the initial g by (1 - D/D0). This value was then multiplied by the number of cycles to obtain the total estimated GA per day.The amount of GA from last fill calculated using the 4-hour D/D0 value from the PET we collected data on HbA1c, LDL, TG at the initiation of dialysis and at least 6 months thereafter. Information regarding the use of glucose-lowering and lipid-lowering medications was obtained, We obtained data from PET test to assess the relation between the amount of GA and the membrane transport character Results: see image Conclusion: Estimated GA did not exceed 115 grams per day, with an average of 78 grams. The majority of patients did not require adjustments to their glucose-lowering medications. no significant changes in HbA1C or lipid profiles noted.The highest amount of GA at 2 hours from PET was among the high and high average transporters. few labs are not avialable as this is a chart review study.larger studies are needed to confirm these findings

  PublisherDOI

Frequent coauthors

• Sandeep K. Mallipattu

  54 shared

• Joel Saltz

  46 shared

• Richard A. Moffitt

  42 shared

• Christopher G. Chute

  Johns Hopkins University

  37 shared

• Melissa Haendel

  University of North Carolina at Chapel Hill

  36 shared

• Emily Pfaff

  Weill Cornell Medicine

  34 shared

• Stephanie Hong

  Johns Hopkins University

  32 shared

• Richard L. Zhu

  Cohort (United Kingdom)

  31 shared

Education

• M.D., Medicine

  Stony Brook University School of Medicine

  1996

• Ph.D., Immunology

  Stony Brook University

  1991

• B.S., Biology

  Stony Brook University

  1987

Awards & honors

• Stony Brook Star Award for Excellence in Clinical Work (2024…